^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRAS G12

    i
    Other names: NRAS1, HRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
    Entrez ID:
    4893
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Apply
    A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P) (NCT05726864)
    Phase 1/2
    Elicio Therapeutics
    Recruiting
    Last update posted :
    03/14/2023
    Initiation :
    03/01/2023
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    KRAS • NRAS
    |
    KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V
    |
    ELI-002
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/28/2023
    Initiation :
    08/14/2014
    Primary completion :
    08/25/2021
    Completion :
    01/12/2024
    BRAF • KRAS • NRAS • HRAS • TG
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • NRAS Q61 • KRAS G12 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61
    |
    Mekinist (trametinib)
    A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201) (NCT04853017)
    Phase 1
    Elicio Therapeutics
    Recruiting
    Last update posted :
    02/10/2023
    Initiation :
    10/04/2021
    Primary completion :
    01/26/2023
    Completion :
    07/01/2025
    KRAS • NRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12
    |
    ELI-002 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • Promune (agatolimod)
    A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (NCT03953235)
    Phase 1/2
    Gritstone bio, Inc.
    Active, not recruiting
    Last update posted :
    02/07/2023
    Initiation :
    07/18/2019
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    KRAS
    |
    KRAS G12C • KRAS G12D • KRAS G13D • NRAS Q61 • NRAS Q61R • KRAS G12 • NRAS G12 • NRAS Q61L • NRAS G13D • CTNNB1 S45P • NRAS G12V • KRAS expression • NRAS G12C
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • SLATE-KRAS
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03190941)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/24/2023
    Initiation :
    09/21/2017
    Primary completion :
    06/29/2027
    Completion :
    06/29/2028
    KRAS • ALK • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • NRAS G12V
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients (NCT03745326)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    01/23/2023
    Initiation :
    05/16/2019
    Primary completion :
    12/01/2027
    Completion :
    12/01/2028
    EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS
    |
    PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • anti-KRAS G12D mTCR PBL
    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors (NCT03454035)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    12/05/2022
    Initiation :
    01/30/2018
    Primary completion :
    07/15/2024
    Completion :
    04/24/2026
    BRAF • KRAS • NRAS • HRAS • NF1 • CA 19-9
    |
    BRAF V600 • NF1 mutation • RAS mutation • NRAS Q61 • KRAS G12 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61
    |
    Ibrance (palbociclib) • ulixertinib (BVD-523) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma (NCT04109456)
    Phase 1
    InxMed (Shanghai) Co., Ltd.
    Recruiting
    Last update posted :
    11/22/2022
    Initiation :
    03/16/2020
    Primary completion :
    12/30/2023
    Completion :
    06/30/2024
    NRAS
    |
    NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • IN10018
    Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer (NCT04146298)
    Phase 1/2
    Changhai Hospital
    Recruiting
    Last update posted :
    06/15/2022
    Initiation :
    10/21/2021
    Primary completion :
    12/01/2024
    Completion :
    03/01/2025
    KRAS • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • NRAS G12V • KRAS expression
    |
    cyclophosphamide • fludarabine IV • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
    Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION (DETECTION) (NCT04901988)
    Phase 2/3
    The Christie NHS Foundation Trust
    Recruiting
    Last update posted :
    11/18/2021
    Initiation :
    11/08/2021
    Primary completion :
    10/01/2030
    Completion :
    10/01/2030
    BRAF • NRAS
    |
    BRAF V600E • BRAF V600 • BRAF V600K • NRAS Q61K • NRAS Q61 • NRAS Q61R • NRAS G12D • NRAS G12 • NRAS Q61L • BRAF V600R
    |
    Opdivo (nivolumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)